# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2018-11-14
- Accepted by EDGAR: Nov 14, 2018, 16:37 ET
- Period: 2018-09-30
- Accession: 0001144204-18-059990
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000114420418059990/tv506610_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000114420418059990/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $52.4k | us-gaap:Revenues |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $66.8k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $36.4k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $41.3k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | $16.0k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $25.5k | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $2.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $10.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$274.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$793.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-07-01 to 2018-09-30 | $377.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-01-01 to 2018-09-30 | $981.3k | us-gaap:InterestExpense |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | −$15.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$756.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2018-09-30 | $172.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $186.8k | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $355.6k | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $7.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $7.7m | us-gaap:Liabilities |
| Long-term debt | at 2018-09-30 | $987.8k | us-gaap:LongTermDebt |
| Shareholders' equity | at 2018-09-30 | −$7.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1187953/000114420418059990/tv506610_10q.htm

Filed Nov 14, 2018.
Source: SEC EDGAR, the filing index for accession 0001144204-18-059990. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
